CORD-PICO  

CORD-19:0036b28fddf7e93da0970303672934ea2f9944e7 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
p2_i0 25-54 Pharmacological denotes unconjugated fecal bile acids
p1_all0 58-156 Population denotes dogs with diabetes mellitus ESCG-O-2 Impact of antibiotic administration on fecal bacterial groups
p2_i1 105-130 Pharmacological denotes antibiotic administration
p2_i2 478-489 Pharmacological denotes antibiotics
p1_all1 799-814 Intervention denotes oral pimobendan
p2_i3 799-814 Pharmacological denotes oral pimobendan
p1_all2 818-878 Outcome denotes left atrial function and mitral valve regurgitation severity
p1_all3 882-932 Population denotes dogs with stage B2 myxomatous mitral valve disease
p2_p0 892-932 Condition denotes stage B2 myxomatous mitral valve disease
p1_all4 989-1012 Outcome denotes safety and tolerability
p1_all5 1016-1026 Intervention denotes pimobendan
p2_i4 1016-1026 Pharmacological denotes pimobendan
p1_all6 1030-1101 Population denotes cats with obstructive versus nonobstructive hypertrophic cardiomyopathy
p2_p1 1040-1101 Condition denotes obstructive versus nonobstructive hypertrophic cardiomyopathy
p2_o2 1210-1217 Physical denotes Blautia
p1_all7 1346-1362 Outcome denotes Faecalibacterium
p2_o4 1346-1362 Physical denotes Faecalibacterium
p2_i5 1530-1557 Pharmacological denotes amoxicillin/clavulanic acid
p1_all8 1530-1572 Intervention denotes amoxicillin/clavulanic acid or doxycycline
p2_i6 1561-1572 Pharmacological denotes doxycycline
p1_all9 1742-1772 Population denotes dogs with chronic enteropathy.
p1_all10 2076-2138 Population denotes healthy dogs and dogs with CE by fecal DNA shotgun sequencing.
p1_all11 2173-2231 Population denotes 14 healthy dogs and 20 dogs with chronic enteropathy (CE).
p1_all12 2632-2662 Outcome denotes low abundance of Bacteroidetes
p2_o16 2632-2662 Physical denotes low abundance of Bacteroidetes
p1_all13 2753-2765 Outcome denotes Fusobacteria
p2_o17 2753-2765 Physical denotes Fusobacteria
p1_all14 2940-2963 Outcome denotes total metabolic modules
p1_all15 3017-3204 Outcome denotes Genes for carbohydrate metabolism, biosynthesis of amino acids (lysine, threonine, histidine, isoleucine, tryptophan, leucine and serine) and vitamins (ascorbate, thiamine and riboflavin)
p1_all16 3513-3541 Outcome denotes altered microbial metabolism
p1_all17 3614-3666 Outcome denotes amino acid biosynthesis and carbohydrate metabolism.
p2_o21 3642-3665 Physical denotes carbohydrate metabolism
p1_all18 3806-3840 Intervention denotes 'Protein-losing-enteropathy' (PLE)
p2_i7 3806-3840 Physical denotes 'Protein-losing-enteropathy' (PLE)
p1_all19 4427-4524 Population denotes all pugs diagnosed with PLE between 2009 and 2018 in five referral centres in the United Kingdom.
p2_o31 4905-4913 Mortality denotes survival
p1_all20 5253-5370 Population denotes A total of 35 pugs were diagnosed with a PLE between 2009 and 2018 and were compared with 113 dogs from other breeds.
p1_all21 5426-5434 Outcome denotes survival
p1_all22 5785-5800 Outcome denotes hazard of dying
p2_o36 5785-5800 Mortality denotes hazard of dying
p1_all23 5941-5961 Outcome denotes hazard risk of death
p2_o36 5941-5961 Mortality denotes hazard risk of death
p1_all24 6273-6276 Intervention denotes PLE
p1_all25 6402-6405 Intervention denotes AJG
p1_all26 6544-6547 Intervention denotes AJG
p1_all27 6835-6843 Intervention denotes ESCG-O-5
p1_all28 6947-6970 Intervention denotes hypo-or hyperfolataemia
p1_all29 6974-7156 Population denotes dogs with chronic enteropathies A. Petrelli, S. Salavati Royal (Dick) School of Veterinary Studies and the Roslin Institute, Edinburgh, United Kingdom Assessment of serum folate (SF)
p2_o48 7475-7551 Physical denotes prevalence of hypo-and hyperfolataemia and the clinical and prognostic value
p1_all30 7657-7687 Outcome denotes prevalence of SF abnormalities
p2_o49 7657-7687 Physical denotes prevalence of SF abnormalities
p1_all31 7777-7915 Population denotes Files of dogs presented for chronic gastrointestinal (GI) signs (> 3 weeks duration) between 2014 and 2017 were retrospectively evaluated.
p2_o50 7805-7840 Physical denotes chronic gastrointestinal (GI) signs
p1_all32 8018-8105 Population denotes 321 dogs (100 FN, 109 MN, 34 FE, 78 ME; median age of 65 m, range 2-171) were included.
p1_all33 8106-8120 Outcome denotes Hypofolataemia
p2_o53 8106-8120 Physical denotes Hypofolataemia
p1_all34 8150-8165 Outcome denotes hyperfolataemia
p1_all35 8387-8396 Outcome denotes SF values
p2_o55 8387-8396 Physical denotes SF values
p1_all36 8528-8618 Outcome denotes food-(FRE), antibiotic-(ARE), steroid-responsive (SRE) or protein-losing enteropathy (PLE)
p2_o56 8528-8618 Physical denotes food-(FRE), antibiotic-(ARE), steroid-responsive (SRE) or protein-losing enteropathy (PLE)
p1_all37 8637-8646 Outcome denotes SF values
p2_o56 8637-8646 Physical denotes SF values
p1_all38 8773-8788 Outcome denotes serum cobalamin
p2_o57 8773-8788 Physical denotes serum cobalamin
p1_all39 8802-8822 Outcome denotes alkaline phosphatase
p2_o57 8802-8822 Physical denotes alkaline phosphatase
p1_all40 8835-8846 Outcome denotes cholesterol
p2_o57 8835-8846 Physical denotes cholesterol
p1_all41 8862-8875 Outcome denotes total calcium
p2_o57 8862-8875 Physical denotes total calcium
p2_o58 9031-9042 Physical denotes cholesterol
p1_all42 9059-9072 Outcome denotes total calcium
p2_o58 9059-9072 Physical denotes total calcium
p1_all43 9349-9375 Outcome denotes clinical signs or survival
p1_all44 9571-9593 Intervention denotes folate supplementation
p2_i8 9571-9593 Pharmacological denotes folate supplementation
p2_i9 9621-9635 Pharmacological denotes hypofolataemia
p1_all45 9705-9749 Outcome denotes Acute haemorrhagic diarrhoea syndrome (AHDS)
p2_i10 9780-9791 Pharmacological denotes antibiotics
p1_all46 10318-10403 Population denotes hospitalized dogs with acute haemorrhagic diarrhoea that did not receive antibiotics.
p1_all47 10514-10678 Population denotes dogs with acute haemorrhagic diarrhoea of unknown aetiology, hospitalized at the University Hospital for Companion Animals during the period 25/2-2014 to 9/10-2018.
p1_all48 11016-11106 Outcome denotes number of SIRS criteria (tachycardia (HR > 120), tachypnea (RR > 40), hyper or hypothermia
p1_all49 11133-11145 Outcome denotes leucocytosis
p1_all50 11167-11177 Outcome denotes leukopenia
p2_o71 11167-11177 Physical denotes leukopenia
p2_o71 11201-11234 Physical denotes neutrophilia and/or hypoglycaemia
p2_p2 11271-11298 Sample-size denotes One-hundred and seventy-two
p1_all51 11271-11553 Population denotes One-hundred and seventy-two dogs were excluded from the analysis due to suspected drug induced disease (vaccination(s) (N = 4), anaesthetics (N = 5), corticosteroids or NSAIDs (N = 81)), alimentary foreign body (N = 5) or treatment with antibiotics during hospitalization (N = 128).
p2_i11 11421-11446 Pharmacological denotes corticosteroids or NSAIDs
p1_all52 11602-11611 Outcome denotes diarrhoea
p2_o73 11602-11611 Physical denotes diarrhoea
p1_all53 12199-12248 Outcome denotes mean AHDS-score after 24 hours of hospitalization
p2_o76 12199-12248 Other denotes mean AHDS-score after 24 hours of hospitalization
p2_p3 12367-12370 Sample-size denotes 128
p1_all54 12367-12406 Population denotes 128 dogs had a degenerative left-shift.
p1_all55 12434-12455 Intervention denotes antimicrobial therapy
p1_all56 12459-12497 Population denotes dogs with acute haemorrhagic diarrhoea
p2_o79 12469-12497 Physical denotes acute haemorrhagic diarrhoea
p1_all57 12618-12648 Outcome denotes faecal bile acid (BA) profiles
p1_all58 12652-12681 Population denotes dogs with chronic enteropathy
p1_all59 12755-12779 Outcome denotes faecal BA concentrations
p2_o81 12755-12779 Physical denotes faecal BA concentrations
p1_all60 12783-12839 Population denotes dogs with acute haemorrhagic diarrhoea syndrome (AHDS-D)
p1_all61 12879-12907 Intervention denotes healthy control dogs (HC-D).
p1_all62 12908-12953 Population denotes Twenty-five AHDS-D and 53 HC-D were enrolled.
p1_all63 12954-12978 Outcome denotes Faecal BA concentrations
p2_o83 12954-12978 Physical denotes Faecal BA concentrations
p1_all64 13288-13321 Outcome denotes concentration of lithocholic acid
p2_o84 13288-13321 Physical denotes concentration of lithocholic acid
p1_all65 13392-13407 Outcome denotes total faecal BA
p2_o85 13392-13407 Physical denotes total faecal BA
p2_o85 13493-13503 Physical denotes primary BA
p1_all66 13590-13618 Outcome denotes concentration of cholic acid
p2_o85 13590-13618 Physical denotes concentration of cholic acid
p2_o85 13638-13650 Physical denotes secondary BA
p1_all67 13717-13751 Outcome denotes concentrations of deoxycholic acid
p2_o85 13717-13751 Physical denotes concentrations of deoxycholic acid
p1_all68 13768-13795 Intervention denotes ursodeoxycholic acid (UDCA)
p1_all69 13857-13888 Outcome denotes total primary BA concentrations
p2_o86 13857-13888 Physical denotes total primary BA concentrations
p1_all70 13926-13955 Outcome denotes concentrations of cholic acid
p2_o86 13926-13955 Physical denotes concentrations of cholic acid
p1_all71 13972-13988 Outcome denotes deoxycholic acid
p2_o86 13972-13988 Physical denotes deoxycholic acid
p1_all72 14072-14090 Outcome denotes faecal BA profiles
p2_o87 14072-14090 Physical denotes faecal BA profiles
p2_o88 14118-14136 Physical denotes faecal BA profiles
p1_all73 14255-14265 Intervention denotes Pimobendan
p2_i12 14255-14265 Pharmacological denotes Pimobendan
p1_all74 14312-14396 Population denotes cats with congestive heart failure (CHF) secondary hypertrophy cardiomyopathy (HCM).
p1_all75 14436-14446 Intervention denotes pimobendan
p2_i13 14436-14446 Pharmacological denotes pimobendan
p1_all76 14464-14523 Population denotes cats with HCM and dynamic outflow tract obstruction (HOCM).
p1_all77 14566-14589 Outcome denotes safety and tolerability
p2_o91 14566-14589 Other denotes safety and tolerability
p1_all78 14593-14603 Intervention denotes pimobendan
p2_i14 14593-14603 Pharmacological denotes pimobendan
p1_all79 14607-14672 Population denotes cats with CHF secondary to HOCM compared with nonobstructive HCM.
p1_all80 14694-14803 Population denotes 94 cats with CHF (47 with HOCM, 47 with nonobstructive HCM) at two tertiary referral hospitals were reviewed.
p1_all81 14990-15009 Outcome denotes Average age of cats
p1_all82 15136-15167 Outcome denotes manifest CHF as pulmonary edema
p2_o95 15145-15167 Physical denotes CHF as pulmonary edema
p1_all83 15224-15240 Outcome denotes pleural effusion
p2_o95 15224-15240 Physical denotes pleural effusion
p1_all84 15306-15319 Outcome denotes heart murmurs
p2_o96 15306-15319 Physical denotes heart murmurs
p1_all85 15401-15411 Intervention denotes Pimobendan
p2_i15 15557-15567 Pharmacological denotes pimobendan
p1_all86 15797-15890 Outcome denotes adverse effects of pimobendan (vomiting, diarrhea, anorexia, lethargy, new-onset arrhythmias)
p2_o99 15828-15890 Adverse-effects denotes vomiting, diarrhea, anorexia, lethargy, new-onset arrhythmias)
p1_all87 16103-16113 Intervention denotes Pimobendan
p2_i16 16103-16113 Pharmacological denotes Pimobendan
p2_o101 16209-16228 Adverse-effects denotes lethargy and nausea
p2_i17 16249-16259 Pharmacological denotes pimobendan
p1_all88 16316-16326 Intervention denotes Pimobendan
p2_i18 16316-16326 Pharmacological denotes Pimobendan
p2_o103 16622-16693 Adverse-effects denotes acute adverse hemodynamic effects (hypotension, cardiovascular collapse
p1_all89 16622-16694 Outcome denotes acute adverse hemodynamic effects (hypotension, cardiovascular collapse)
p1_all90 16767-16777 Intervention denotes pimobendan
p2_i19 16767-16777 Pharmacological denotes pimobendan
p1_all91 16799-16831 Population denotes cats with cardiomyopathy and CHF
p1_all92 16894-16921 Outcome denotes Systolic heart murmurs (SM)
p2_o105 16894-16921 Physical denotes Systolic heart murmurs (SM)
p1_all93 16948-16961 Population denotes healthy cats.
p1_all94 17064-17069 Population denotes cats.
p2_o107 17131-17195 Physical denotes septal bulge, systolic anterior motion of the mitral valve (SAM)
p1_all95 17131-17237 Outcome denotes septal bulge, systolic anterior motion of the mitral valve (SAM) and increased aortic flow velocity (AoV).
p2_o107 17210-17236 Physical denotes aortic flow velocity (AoV)
p1_all96 17238-17366 Population denotes Between November 2014 and February 2018, 316 client owned cats referred for a cardiology evaluation were prospectively examined.
p2_o112 17773-17793 Physical denotes Urinary ET-1 (UET-1)
p2_o113 18001-18020 Physical denotes renal ET-1 activity
p1_all97 18034-18085 Population denotes advanced canine chronic cardiac and renal diseases.
p2_p4 18438-18448 Sample-size denotes forty-four
p1_all98 18438-18667 Population denotes forty-four client-owned cats with asymptomatic hypertrophic cardiomyopathy (aHCM). Cats with diastolic interventricular septum (IVSd) and/or left ventricular wall (LVWd) thickness ≥ 6 mm were included after informed ownerconsent.
p2_p5 18449-18512 Condition denotes client-owned cats with asymptomatic hypertrophic cardiomyopathy
p2_i20 18683-18852 Physical denotes non-sedated, fasted cats before and after 6 and 12 months of test or control diet included auscultation, bodyweight (BW), body condition score (BCS) and echocardiography
p2_o116 18774-18831 Physical denotes auscultation, bodyweight (BW), body condition score (BCS)
p1_all99 18774-18858 Outcome denotes auscultation, bodyweight (BW), body condition score (BCS) and echocardiography. Wall
p2_o118 18854-18858 Physical denotes Wall
p1_all100 18925-18956 Outcome denotes blood pressure (BP) recordings.
p1_all101 19099-19165 Population denotes healthy cats. Ninety-six healthy cats were prospectively included.
p2_p6 19113-19123 Sample-size denotes Ninety-six
p1_all102 19170-19282 Outcome denotes health examination included physical examination, echocardiography, hematology, and biochemistry. Blood pressure
p2_o122 19268-19282 Physical denotes Blood pressure
p1_all103 19393-19541 Intervention denotes (1) cat taken out of its carrier and placed on examination table with veterinarian present, (2) cat in its own carrier with veterinarian present, or